Karl A. Hansford

TL;DR: In this review, the discovery, development and associated resistance of vancomycin and teicoplanin, and semi-synthetic glycopeptides, telavancin (3), dalbavancein (4) and oritavancIn (5), are detailed and the clinical implications of glycopePTide resistance, as well as the future prospects for current glycopesptide drugs and the development of new glycopeptic drugs are discussed.

TL;DR: Next-generation glycopeptides are now technically well positioned to advance to the clinic, if sufficient funding and market support returns to antibiotic development.

TL;DR: The rejuvenation of the glycopeptide antibiotic vancomycin is described via selective targeting of bacterial membranes to ‘revitalise’ antibiotics that have lost effectiveness against recalcitrant bacteria, or enhance the activity of other intravenous-administered drugs that target membrane-associated receptors.

TL;DR: The simple chiral precursor D‐tyrosine was derivatised to give a series of potent new inhibitors of hnpsPLA2‐IIa, which inhibit the IIa human isoform noncovalently at submicromolar concentrations.

TL;DR: Chemoselective hydrolysis of tert-butyl esters in the presence of other acid-labile groups has been explored by employing alpha-amino esters and ZnBr(2) in DCM and PhF protected amines were compatible with these Lewis acid deprotection conditions such that a variety of N-(PhF)amino acids were prepared in good yields.